Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 1;1(8):1398-1400.
doi: 10.4161/onci.20982.

Targeting dendritic cells in situ for breast cancer immunotherapy

Bei Wang  1
Affiliations

Targeting dendritic cells in situ for breast cancer immunotherapy

Bei Wang. Oncoimmunology. .

Abstract

We have recently developed a protein vaccine against breast cancer in which HER2 is delivered to dendritic cells (DCs) in vivo through receptors expressed on their surface. Our results indicate that this is a promising approach to induce durable, broad and integrated immunity against breast cancer.

PubMed Disclaimer

Figures

None
Figure 1. Induction of T-cell immunity against breast cancer through a HER2 protein vaccine targeted to dendritic cells (DCs) in vivo. Maturation of DCs is induced by the Toll-like receptor 3 (TLR3 = ligand polyI:C. HER2 protein is delivered to DCs via an anti-DEC205 hybrid antibody. DCs are able to process the HER2 protein to liberate peptides for presentation on MHC Class I and II complexes to CD8+ and CD4+ T cells, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
    Goyvaerts C, Breckpot K. Goyvaerts C, et al. J Immunol Res. 2015;2015:785634. doi: 10.1155/2015/785634. Epub 2015 Oct 25. J Immunol Res. 2015. PMID: 26583156 Free PMC article. Review.
  • Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer.
    Kini Bailur J, Gueckel B, Pawelec G. Kini Bailur J, et al. J Transl Med. 2016 May 28;14(1):151. doi: 10.1186/s12967-016-0905-x. J Transl Med. 2016. PMID: 27234566 Free PMC article.
  • Trial watch: Dendritic cell-based anticancer therapy.
    Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Bloy N, et al. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941593 Free PMC article. Review.
  • Classification of current anticancer immunotherapies.
    Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
  • Trial watch: Dendritic cell-based interventions for cancer therapy.
    Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2013 Oct 1;2(10):e25771. doi: 10.4161/onci.25771. Epub 2013 Jul 29. Oncoimmunology. 2013. PMID: 24286020 Free PMC article. Review.
See all "Cited by" articles

References

    1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75. doi: 10.1038/nrc2656. - DOI - PubMed
    1. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790–802. doi: 10.1038/nri2173. - DOI - PubMed
    1. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995;375:151–5. doi: 10.1038/375151a0. - DOI - PubMed
    1. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med. 2012;271:183–92. doi: 10.1111/j.1365-2796.2011.02496.x. - DOI - PMC - PubMed
    1. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res. 2012;14:R39. doi: 10.1186/bcr3135. - DOI - PMC - PubMed